Treatment-resistant depression

Pelorus Elder & Behavioral Health Opens Pelorus TMS Therapy Center in Raritan, NJ

Retrieved on: 
Friday, June 25, 2021
Mind, Self, Branches of biology, Psychiatric diagnosis, Neuropsychology, Major depressive disorder, Abnormal psychology, Management of depression, Treatment-resistant depression, Pelorus, Depression, Transcranial magnetic stimulation

Pelorus uses NeuroStar TMS Machines leveraging magnetic fields to stimulate the regions of the brain associated with depression.

Key Points: 
  • Pelorus uses NeuroStar TMS Machines leveraging magnetic fields to stimulate the regions of the brain associated with depression.
  • NeuroStar TMS treatment shows beneficial outcomes for patients that have yet to find a successful treatment for depression.
  • If you or a loved one has been struggling with treatment resistant depression, schedule a consultation or an appointment with Pelorus TMS.
  • Call today at 973-295-6335 or check out the Pelorus website to see if NeuroStar TMS Therapy may be the right fit for you.

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

Retrieved on: 
Thursday, June 3, 2021
Clinical research, Psychoactive drugs, Entheogens, Medical research, Health sciences, Mycotoxins, Organophosphates, Psilocybin, Treatment-resistant depression, Placebo

The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg) compared with placebo in 89 healthy male and female adult volunteers.

Key Points: 
  • The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg) compared with placebo in 89 healthy male and female adult volunteers.
  • The participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29).
  • The results are encouraging and we are looking forward to reporting data from our phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) later this year.
  • Dr Rucker said: This study, the largest randomised placebo-controlled trial of psilocybin to date, found that COMP360 psilocybin had no clinically-relevant negative effect on cognitive function.

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

Retrieved on: 
Wednesday, June 2, 2021
Psychiatric diagnosis, Branches of biology, Medical specialties, Medicine, Major depressive disorder, Alzheimer's disease, Neuroinflammation, Treatment-resistant depression

We are pleased that USAN has approved pegipanermin as the generic name for XPro1595, stated RJ Tesi, MD, Chief Executive Officer of INmune Bio.

Key Points: 
  • We are pleased that USAN has approved pegipanermin as the generic name for XPro1595, stated RJ Tesi, MD, Chief Executive Officer of INmune Bio.
  • In the near term, we will be evaluating pegipanermin as a potential treatment for Alzheimers disease and treatment resistant depression.
  • INmune reported positive Phase 1b Alzheimers data in January 2021 demonstrating that XPro1595 decreased neuroinflammation and neurodegeneration biomarkers in patients with mild to moderate Alzheimers.
  • The company is planning to initiate two Phase 2 clinical trials of XPro1595, in Alzheimers and Treatment Resistant Depression, in 2021.

Greenbrook TMS Announces Preliminary First Quarter 2021 Operational and Financial Results

Retrieved on: 
Tuesday, May 4, 2021
Biotechnology, General Health, Mental health, Medical devices, Health, Psychiatric diagnosis, Psychiatry, Major depressive disorder, Drug resistance, Treatment-resistant depression, Obsessive–compulsive disorder, Medicine, Clinical medicine

b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).

Key Points: 
  • b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).
  • We are proud of our team\xe2\x80\x99s efforts to continue to treat patients suffering from treatment resistant depression and obsessive-compulsive disorder during this difficult time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

Using Rapid-Acting Brain Stimulation for Treatment-Resistant Depression - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Medicine, Neuroscience, Neurotechnology, Electrotherapy, Medical devices, Neurophysiology, Neuropsychology, Brain & Behavior Research Foundation, Transcranial magnetic stimulation, Treatment-resistant depression, Brain stimulation

b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.

Key Points: 
  • b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.
  • Past research has demonstrated that a form of FDA-approved non-invasive brain stimulation called rTMS could be optimized to better treat depression as well as other psychiatric disorders.
  • Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series \xe2\x80\x9cHealthy Minds,\xe2\x80\x9d will be the moderator.
  • Join by phone or on the web at bbrf.org/maywebinar.\nThis webinar is part of a series of free monthly \xe2\x80\x9cMeet the Scientist\xe2\x80\x9d webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms

Retrieved on: 
Wednesday, April 28, 2021
Psychiatry, Psychiatric diagnosis, Human behavior, Mind, Anxiety disorders, Magical thinking, Obsessive–compulsive disorder, Ritual, Abnormal psychology, Delayed-maturation theory of obsessive-compulsive disorder, Treatment-resistant depression

b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).

Key Points: 
  • b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
  • In addition, MagVenture TMS Therapy can reduce the symptoms of comorbid anxiety in patients suffering from depression.
  • "\nFor OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group.
  • "\nFor subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.\n'

Myconic Capital Corp. Signs Letter of Intent for Acquisition of NY Ketamine Medical Practice, PLLC

Retrieved on: 
Monday, April 5, 2021
Drugs, Psychoactive drugs, Clinical medicine, Antidepressants, NMDA receptor antagonists, General anesthetics, Nicotinic antagonists, Sedatives, Ketamine, Treatment-resistant depression, Intravenous therapy

In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.

Key Points: 
  • In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.
  • Based on the success of its New York City clinic, NY Ketamine Infusions has opened an additional clinic in Long Island, NY (Melville).
  • Dr. Brooks also continues to act as a consultant for privately owned practices in Albany, NY and Madrid, Spain.
  • Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

COMPASS Pathways granted two US patents

Retrieved on: 
Tuesday, March 23, 2021
Health, Psychiatric diagnosis, Major depressive disorder, Drug resistance, Treatment-resistant depression, Mental health, Health care

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO).

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO).
  • These patents cover oral formulations of COMPASSs synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).
  • These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US, said George Goldsmith, CEO and Co-founder of COMPASS Pathways.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

Retrieved on: 
Thursday, March 11, 2021
Psychiatric diagnosis, Major depressive disorder, Mind, Psychiatry, Psychology, Mood disorders, Abnormal psychology, Drug resistance, Treatment-resistant depression, Management of depression, TRD, Bipolar disorder

The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
  • For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends
    Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options.
  • According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017.

Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

Retrieved on: 
Thursday, March 11, 2021
Psychiatric diagnosis, Major depressive disorder, Mind, Psychiatry, Psychology, Mood disorders, Abnormal psychology, Drug resistance, Treatment-resistant depression, Management of depression, TRD, Bipolar disorder

The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
  • For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends
    Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options.
  • According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017.